secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104587
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q2 net loss $21.2M; cash $148.3M; Phase 2 interim analysis webinar Sept 10
--------------------------------------------------------------------------------

- Net loss $21.2M for Q2 2025 vs $1.2M in Q2 2024, due to prior-year $16.2M tax benefit from NOL sale.
- Cash, equivalents, and marketable securities $148.3M as of June 30, 2025, expected runway to end of 2026.
- R&D expenses $18.4M (up 26% YoY) driven by contractual research costs for rezatapopt program.
- Investor webinar Sept 10 to review Phase 2 PYNNACLE interim data; ~65 patients, ~45% ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/0000950170-25-104587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer